Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring... see more

Recent & Breaking News (CSE:BUX)

BioMark Announces Warrant Extension and Granting of Options

Newsfile April 18, 2024

BioMark to Advance Development of Cancer Treatment for Glioblastoma

Newsfile April 9, 2024

BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities

Newsfile February 28, 2024

Theresa Peterson Joins Biomark's Advisory Team

Newsfile February 26, 2024

BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement

Newsfile December 29, 2023

BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

Newsfile December 4, 2023

BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

Newsfile November 28, 2023

BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives

Newsfile November 14, 2023

BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test

Newsfile November 7, 2023

BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium

Newsfile October 24, 2023

BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team

Newsfile August 30, 2023

Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay

Newsfile August 8, 2023

BioMark Issues Statement on Recent Market Activity and Provides a Brief Corporate Update

Newsfile July 25, 2023

BioMark unveils significant scientific lung cancer research advancements at ASCO 2023

Jonathon Brown June 5, 2023

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

Newsfile June 5, 2023

BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay

Newsfile May 31, 2023

BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

Newsfile May 3, 2023

Advancing new methods to detect rare tumors early

Jonathon Brown March 17, 2023

BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors

Newsfile March 16, 2023

BioMark Provides Third Quarter Operational Update and 2023 Outlook

Newsfile March 1, 2023